Pyxis Oncology, Inc. Share Price

Pyxis Oncology, Inc. Share Price

NASDAQ: PYXS | Micro Cap
$1.89
-$0.09 (-4.3%) Last updated on 30 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Pyxis Oncology, Inc. Stock Performance

Open
$1.98
Prev. Close
$1.98
Circuit Range
N/A
Day Range
$1.89 - $1.98
Year Range
$1.03 - $5.55
Volume
45,254
Average Traded
$1.92

Pyxis Oncology, Inc. Share Price Today

As of 30 October 2026, Pyxis Oncology, Inc.'s share price is $1.89. The stock opened at $1.98, compared to its previous close of $1.98. During today's trading session, Pyxis Oncology, Inc.'s share price traded between $1.89 and $1.98, with an average price of $1.93. Over the past 52 weeks, the stock has recorded a high of $5.55 and a low of $1.03. In terms of performance, Pyxis Oncology, Inc.'s share price has risen by 10.85% over the last six months and is down 47.13% on a year-on-year basis.

Pyxis Oncology, Inc. Share Price Chart

Line chart of the Pyxis Oncology, Inc. price trend over the selected period. The price fell overall, ranging from 1.89 to 1.98, ending at 1.89.
$1.89$1.98
L
Show Current Price
H

Pyxis Oncology, Inc. Stock Fundamentals & Key Indicators

Market Cap
$117.45M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.06
Revenue (TTM)
$13.86B
Return On Equity (TTM)
-775.59%
Profit Margin
-574.46%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-15.23%

Pyxis Oncology, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$11.04$0.00$0.00
Net Profit-$22.00-$18.11-$23.27-$25.35
Net Profit MarginN/A-164.04%N/AN/A
Income ChangeN/A17.68%-28.49%-8.94%

Pyxis Oncology, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.00$16.15$13.86
Net Profit-$120.72-$73.79-$77.33-$79.62
Net Profit MarginN/AN/A-478.82%-574.46%
Income ChangeN/A38.88%-4.80%-2.96%

About Pyxis Oncology, Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Pyxis Oncology, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$2.27
$1.89
-18.75%
Sep 2026
$3.27
$2.32
-30.54%
Aug 2026
$2.79
$3.34
+26.52%
Jul 2026
$3.06
$2.64
-12.00%
Jun 2026
$1.81
$3.00
+66.20%
May 2026
$1.69
$1.80
+5.87%
Apr 2026
$1.52
$1.71
+16.78%
Mar 2026
$1.40
$1.46
-1.02%
Feb 2026
$1.49
$1.48
+1.03%
Jan 2026
$1.14
$1.46
+26.41%
Dec 2025
$5.10
$1.16
-77.66%
Nov 2025
$3.65
$5.17
+44.62%

PYXS Share Price FAQs